Australia and New Zealand Endotoxin Testing Market Size: By Product & Services: Endotoxin Detection Kits & Reagents, Instruments, Systems, and Software, Endotoxin Testing Services, Others; By Test Type; By Distribution Channel; By Method; By Mode of Purchase; By Applications; By End User; Regional Analysis; Supplier Landscape; 2024-2032

1    Preface
    1.1    Objectives of the Study
    1.2    Key Assumptions 
    1.3    Report Coverage – Key Segmentation and Scope  
    1.4    Research Methodology
2    Executive Summary
3    Australia and New Zealand Endotoxin Testing Market Overview 
    3.1    Australia and New Zealand Endotoxin Testing Market Historical Value (2017-2023) 
    3.2    Australia and New Zealand Endotoxin Testing Market Forecast Value (2024-2032)
4    Australia and New Zealand Endotoxin Testing Market Dynamics
    4.1    Market Drivers and Constraints
    4.2    SWOT Analysis
    4.3    Porter’s Five Forces Model 
    4.4    Key Demand Indicators
    4.5    Key Price Indicators
    4.6    Industry Events, Initiatives, and Trends 
    4.7    Value Chain Analysis
5    Australia and New Zealand Endotoxin Testing Market Segmentation 
    5.1    Australia and New Zealand Endotoxin Testing Market by Product & Services
        5.1.1    Market Overview                                                                                             
        5.1.2    Endotoxin Detection Kits & Reagents
        5.1.3    Instruments, Systems, and Software
        5.1.4    Endotoxin Testing Services
        5.1.5    Consumables & Accessories
    5.2    Australia and New Zealand Endotoxin Testing Market by Test Type
        5.2.1    Market Overview
        5.2.2    Limulus Amoebocyte Lysate (LAL) Test
        5.2.3    Monocyte Activation Test (MAT)
        5.2.4    Rabbit Pyrogen Test and Recombinant C (RFC) Assay
    5.3    Australia and New Zealand Endotoxin Testing Market by Distribution Channel
        5.3.1    Market Overview
        5.3.2    Pharmacies
        5.3.3    Online Channel
        5.3.4    Hypermarkets
    5.4    Australia and New Zealand Endotoxin Testing Market by Method
        5.4.1    Market Overview
        5.4.2    Gel Clot Endotoxin Test
        5.4.3    Chromogenic Endotoxin Test
        5.4.4    Turbidimetric Endotoxin Test
    5.5    Australia and New Zealand Endotoxin Testing Market by Mode of Purchase
        5.5.1    Market Overview
        5.5.2    Large Group
        5.5.3    Mid and Small Group
        5.5.4    Individual
    5.6    Australia and New Zealand Endotoxin Testing Market by Applications
        5.6.1    Market Overview
        5.6.2    Pharmaceutical Manufacturing
        5.6.3    Medical Device Manufacturing
        5.6.4    Raw Materials Production
        5.6.5    Packaging Manufacture
    5.7    Australia and New Zealand Endotoxin Testing Market by End User
        5.7.1    Market Overview
        5.7.2    Pharmaceutical Companies
        5.7.3    Biotechnology Companies
        5.7.4    Medical Device Companies
        5.7.5    Contract Research Organization (CRO)
        5.7.6    Contract Manufacturing Organization (CMO)
        5.7.7    Academic Research Institute and Others
    5.8    Australia and New Zealand Endotoxin Testing Market by Country
        5.8.1    Market Overview
        5.8.2    Australia
        5.8.3    New Zealand 
6    Patent Analysis
    6.1    Analysis by Type of Patent
    6.2    Analysis by Publication year
    6.3    Analysis by Issuing Authority
    6.4    Analysis by Patent Age
    6.5    Analysis by CPC Analysis
    6.6    Analysis by Patent Valuation 
    6.7    Analysis by Key Players
7    Grants Analysis
    7.1    Analysis by year
    7.2    Analysis by Amount Awarded
    7.3    Analysis by Issuing Authority
    7.4    Analysis by Grant Application
    7.5    Analysis by Funding Institute
    7.6    Analysis by NIH Departments
    7.7    Analysis by Recipient Organization 
8    Funding Analysis
    8.1    Analysis by Funding Instances
    8.2    Analysis by Type of Funding
    8.3    Analysis by Funding Amount
    8.4    Analysis by Leading Players
    8.5    Analysis by Leading Investors
    8.6    Analysis by Geography
9    Partnership and Collaborations Analysis
    9.1    Analysis by Partnership Instances
    9.2    Analysis by Type of Partnership
    9.3    Analysis by Leading Players
    9.4    Analysis by Geography
10    Regulatory Framework
    10.1    Regulatory Overview
11    Supplier Landscape
    11.1    Viatris Inc.
        11.1.1    Financial Analysis
        11.1.2    Product Portfolio
        11.1.3    Demographic Reach and Achievements
        11.1.4    Mergers and Acquisitions
        11.1.5    Certifications
    11.2    Eurofins Scientific
        11.2.1    Financial Analysis
        11.2.2    Product Portfolio
        11.2.3    Demographic Reach and Achievements
        11.2.4    Mergers and Acquisitions
        11.2.5    Certifications
    11.3    Thermo Fisher Scientific
        11.3.1    Financial Analysis
        11.3.2    Product Portfolio
        11.3.3    Demographic Reach and Achievements
        11.3.4    Mergers and Acquisitions
        11.3.5    Certifications
    11.4    Pall Corporation.
        11.4.1    Financial Analysis
        11.4.2    Financial Portfolio
        11.4.3    Demographic Reach and Achievements
        11.4.4    Mergers and Acquisitions
        11.4.5    Certifications
    11.5    Lonza Group AG
        11.5.1    Financial Analysis
        11.5.2    Product Portfolio
        11.5.3    Demographic Reach and Achievements
        11.5.4    Mergers and Acquisitions
        11.5.5    Certifications
    11.6    Charles River Laboratories
        11.6.1    Financial Analysis
        11.6.2    Product Portfolio
        11.6.3    Demographic Reach and Achievements
        11.6.4    Mergers and Acquisitions
        11.6.5    Certifications
    11.7    Merck KGaA
        11.7.1    Financial Analysis
        11.7.2    Product Portfolio
        11.7.3    Demographic Reach and Achievements
        11.7.4    Mergers and Acquisitions
        11.7.5    Certifications
    11.8    Steris Inc.
        11.8.1    Financial Analysis
        11.8.2    Product Portfolio
        11.8.3    Demographic Reach and Achievements
        11.8.4    Mergers and Acquisitions
        11.8.5    Certifications
    11.9    Société Générale de Surveillance SA
        11.9.1    Financial Analysis
        11.9.2    Product Portfolio
        11.9.3    Demographic Reach and Achievements
        11.9.4    Mergers and Acquisitions
        11.9.5    Certifications
    11.10    Sartorius AG
        11.10.1    Financial Analysis
        11.10.2    Product Portfolio
        11.10.3    Demographic Reach and Achievements
        11.10.4    Mergers and Acquisitions
        11.10.5    Certifications
    11.11    GenScript
        11.11.1    Financial Analysis
        11.11.2    Product Portfolio
        11.11.3    Demographic Reach and Achievements
        11.11.4    Mergers and Acquisitions
        11.11.5    Certifications
    11.12    Accugen Labs
        11.12.1    Financial Analysis
        11.12.2    Product Portfolio
        11.12.3    Demographic Reach and Achievements
        11.12.4    Mergers and Acquisitions
        11.12.5    Certifications
    11.13    Sigma-Aldrich
        11.13.1    Financial Analysis
        11.13.2    Product Portfolio
        11.13.3    Demographic Reach and Achievements
        11.13.4    Mergers and Acquisitions
        11.13.5    Certifications
    11.14    Nelson Laboratories and Biosynthesis
        11.14.1    Financial Analysis
        11.14.2    Product Portfolio
        11.14.3    Demographic Reach and Achievements
        11.14.4    Mergers and Acquisitions
        11.14.5    Certifications
    11.15      Pacific BioLabs
        11.15.1    Financial Analysis
        11.15.2    Product Portfolio
        11.15.3    Demographic Reach and Achievements
        11.15.4    Mergers and Acquisitions
        11.15.5    Certifications
12    Australia and New Zealand Endotoxin Testing Market - Distribution Model (Additional Insight)
    12.1    Overview 
    12.2    Potential Distributors 
    12.3    Key Parameters for Distribution Partner Assessment 
13    Key Opinion Leaders (KOL) Insights (Additional Insight)
14    Company Competitiveness Analysis (Additional Insight)
    14.1    Very Small Companies
    14.2    Small Companies
    14.3    Mid-Sized Companies
    14.4    Large Companies
    14.5    Very Large Companies
15    Payment Methods (Additional Insight)
    15.1    Government Funded
    15.2    Private Insurance
    15.3    Out-of-Pocket

*Additional insights provided are customisable as per client requirements.